NASDAQ: COAG
Hemab Therapeutics Holdings, Inc.CIK 0002114044 · Biological Products
10-Q
Filed May 21, 2026
· Period ending Mar 31, 2026
Red flag
Hemab discloses material control weaknesses in debut 10-Q; $317M IPO extends runway to 2029
5 material changes detected. Sign up free to read the summary.
8-K
Filed May 21, 2026
· Period ending May 21, 2026
Hemab Therapeutics reports Q1 2026 financial results
2 material changes detected. Sign up free to read the summary.
Partner
Trade COAG commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed May 11, 2026
· Period ending May 8, 2026
Summary not yet generated.
8-K
Filed May 4, 2026
· Period ending May 4, 2026
Summary not yet generated.